EPISODE · Mar 3, 2022 · 8 MIN
Dr. Fizazi discusses potential benefit of triplet therapy for metastatic hormone-sensitive prostate cancer
from Urology Times Podcasts · host Urology Times
In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Karim Fizazi, MD, PhD, about results from a game-changing study that was presented at the 2022 ASCO Genitourinary Cancers Symposium. The phase 3 ARASENS trial improved overall survival in patients with metastatic hormone-sensitive prostate cancer with triplet therapy. Fizazi is a medical oncologist and head of the department of cancer medicine at the Institute of Gustave Roussy, and professor of oncology at the University of Paris Sud in Villejuif, France.
Embed this episode
What this episode covers
“Obviously, patients benefit [from triplet therapy]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD
NOW PLAYING
Dr. Fizazi discusses potential benefit of triplet therapy for metastatic hormone-sensitive prostate cancer
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.